Literature DB >> 32658415

Hepatitis B Vaccine: Assessment of Immunologic Response, Coverage Rate, and Factors Influencing Seroreactivity.

Abdullah Khafagy, Imad AlJahdaly, Reda Goweda.   

Abstract

BACKGROUND: Hepatitis B infection and resulting health sequela is a worldwide health problem. Adults at increased risk of infection are recommended to receive hepatitis B vaccine for protection, followed by postvaccination titer testing to confirm immunity. The aim of this study is to assess coverage rate and immunologic response to hepatitis B vaccine and factors influencing seroreactivity.
METHODS: This was a cross-sectional study carried out among medical doctors of Makkah city, medical interns, and medical students of Umm Al-Qura University, Saudi Arabia. A self-administered questionnaire was used to collect data for evaluation of hepatitis B vaccination coverage, immune status, and associated risk factors.
RESULTS: Three hundred twenty-one (79.9%) out of 402 participants received the vaccination. Of those vaccinated 159 (48.3%) had subsequent testing for anti-HBs. One hundred thirty-nine (87.4%) had an appropriate immunologic response to the vaccine (titer ≥ 10 mIU/mL). Factors negatively influencing seroreactivity were male gender, high BMI, smoking, incomplete vaccination series, vaccination schedule non-adherence, and long elapsed time since last vaccination; with p-values of 0.001, 0.000, 0.002, 0.001, 0.037, and 0.000, respectively.
CONCLUSIONS: Hep B vaccination coverage in our study is considered insufficient. Smoking and obesity were modi-fiable and preventable risk factors negatively affecting the immunologic response. The development and enforcement of better health policies aimed at increasing access and coverage of the HBV vaccination of at-risk populations like medical students, with increased awareness, is recommended.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32658415     DOI: 10.7754/Clin.Lab.2019.191202

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  2 in total

1.  IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity.

Authors:  John T Bates; Andrew P Farmer; Michael A Bierdeman; Dallas R Ederer; Lauren S Carney; Denise D Montgomery; Seth T Lirette; Gailen D Marshall
Journal:  Vaccines (Basel)       Date:  2022-03-25

2.  Body Mass Index and Antibody Persistence after Measles, Mumps, Rubella and Hepatitis B Vaccinations.

Authors:  Marco Fonzo; Annamaria Nicolli; Stefano Maso; Lorenzo Carrer; Andrea Trevisan; Chiara Bertoncello
Journal:  Vaccines (Basel)       Date:  2022-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.